Earnings ·
Pelthos Therapeutics Inc. reported second quarter 2026 financial results, announcing net product revenue of $15.4…
PTHSPelthos Therapeutics Inc.
Pelthos Therapeutics Inc. reported second quarter 2026 financial results, announcing net product revenue of $15.4 million for its lead drug Zelsuvmi, a 45% increase from the first quarter's $10.7 million. The company dispensed 11,925 units to 4,571 unique prescribers during the quarter. Pelthos reported a net loss of $23.4 million and an adjusted EBITDA loss of $5.7 million. Cash reserves stood at $24.2 million as of June 30, 2026. The filing also references a prior restatement of first quarter 2026 financial statements. Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on developing and marketing treatments for cutaneous infectious diseases.